secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-08-21T23:59:59+00:00
Accession:  0000950170-25-110654
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics receives Nasdaq extension to Feb 17, 2026 for bid price compliance
--------------------------------------------------------------------------------

- Nasdaq notified Atossa on Feb 21, 2025 of non-compliance with $1.00 min bid price rule.
- Initial compliance period ended Aug 20, 2025; extension granted to Feb 17, 2026.
- Company may consider a reverse stock split to regain compliance.
- No immediate impact on Nasdaq listing or trading of ATOS shares.
- Atossa is monitoring bid price and evaluating available options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/0000950170-25-110654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/atos-20250821.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-110654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer